Background. Recent studies have shown a decrease in the incidence of herpes zoster (HZ) among human immunodeficiency virus (HIV)-infected patients since the combined antiretroviral therapy (cART) era, but more data are needed on a possible increase in the risk early after cART initiation.
their incidence and clinical presentation, but little is known of the impact of cART on the incidence of and risk factors for HZ. Although the restoration of cell-mediated immunity on cART is expected to reduce the risk of HZ, treated patients live much longer and may thus become more susceptible to HZ due to the natural decline in cell-mediated immunity associated with aging. Some cohort studies of adults [9] and children [10] suggest that the HZ incidence has not changed significantly since the advent of cART, whereas other studies show a significant decrease [7, 8, [11] [12] [13] [14] [15] . However, HIV infection remains a significant risk factor for HZ, even in the higher CD4 cell strata (>750 cells/µL) [7] . Several studies have shown an increase in HZ incidence during the first months following cART initiation, suggesting that HZ may be a feature of the immune reconstitution inflammatory syndrome (IRIS) [11, [16] [17] . However, longitudinal data on the risk of HZ early after cART initiation are sparse.
As HZ is caused by VZV reactivation, VZV vaccination might help to prevent it. A live attenuated VZV vaccine is licensed in several countries for HZ prevention in persons aged >50 years but is contraindicated in immunodeficient individuals. Two candidate vaccines are currently in development for the prevention of HZ in immunocompromised populations, including HIV-infected patients [18] .
To better inform vaccination policies in Europe, we studied the HZ incidence rate and risk factors in HIV-1-infected patients followed in the French Hospital Database on HIV (FHDH-ANRS CO4 [hereafter referred to as FHDH]) during the years 1992-2011, compared with the general population during the years [2005] [2006] [2007] [2008] . We also studied the early impact of cART initiation in a subgroup of naive patients.
METHODS

Study Population
Patients were selected from the FHDH [19] , a nationwide hospital-based cohort created in 1989. Seventy clinical centers in hospitals across France currently contribute data on HIVinfected patients. The only FHDH inclusion criteria are HIV-1 or HIV-2 infection and written informed consent. Trained research assistants prospectively collect clinical, biological, and therapeutic data at least every 6 months from medical records, using specialized software. Clinical events are collected using the International Classification of Diseases (ICD); the Ninth Revision codes were used prior to 1997 and the Tenth Revision thereafter. The FHDH was approved by the French data protection authority (Commission Nationale de l'Informatique et des Libertés). Patients were not eligible for this study if they were <15 years of age, HIV-2 infected, or not followed between January 1992 and December 2011, and if they had <6 months of follow-up, no CD4 cell count at cohort entry, or a history of VZV infection or ongoing VZV infection at cohort entry. The study was also limited to adults aged <85 years, as <10 cases of HZ occurred beyond this age.
French General Population
The Sentinelles general practitioner (GP) surveillance network provided the incidence of HZ in the background general population in France [20] [21] . Annual incidence rates are corrected for the participating GPs' geographic distribution.
Herpes Zoster Definition
Cases of HZ were extracted from the FHDH and Sentinelles network by using the following (ICD) codes: 53.0-53.9 (ICD-9) and B02.0-B02.9 (ICD-10).
Statistical Analysis
Follow-up time was measured from FHDH enrollment until diagnosis of HZ, death, the last follow-up visit, or 31 December 2011, whichever occurred first. HZ incidence rates were calculated by dividing the observed number of incident HZ cases by the number of person-years (PY) at risk in each of the 5 following calendar periods: the pre-cART period (1992) (1993) (1994) (1995) (1996) , and the cART era, which was divided into 4 periods: early (1997) (1998) (1999) (2000) , intermediate (2001) (2002) (2003) (2004) , late (2005) (2006) (2007) (2008) , and recent (2009) (2010) (2011) . Only first episodes of HZ were considered. To permit temporal comparisons within the HIV-infected population, HZ incidence rates and their 95% confidence intervals (CIs) in each calendar period were standardized for the demographic structure (age in 5-year increments and sex) of all HIV-1-infected patients followed during the cART period (1997-2011), using the direct method.
Factors associated with the risk of HZ in HIV-infected patients were identified by using Cox proportional hazards models including sex, HIV transmission group, age at inclusion in the FHDH, sub-Saharan Africa origin, AIDS status before HZ or at the end of follow-up, the CD4 cell nadir before HZ or before the end of follow-up, the current CD4 cell count, and either cART use or the calendar period as a proxy of treatment exposure. Combination ART was defined as a combination of ≥3 drugs or a dual therapy with 2 boosted protease inhibitors (PIs) or 1 boosted PI plus 1 nonnucleoside reverse transcriptase inhibitor; or at least 1 boosted PI combined with an integrase inhibitor and/or an anti-CCR5 drug; or boosted PI monotherapy, whatever the PI. The pre-cART period or the late cART period (2005-2011) was used as the reference calendar period. For continuous variables, the choice between continuous and categorical classification was based on the lowest value of Akaike information criterion for the corresponding univariable Cox regression model. The reference category for age was the median age class. We used the 1993 Centers for Disease Control and Prevention (CDC) clinical AIDS case definition. Models restricted to patients followed after 1996, when HIV RNA assaying techniques became widely available, were adjusted for the plasma HIV RNA level and CD4/CD8 ratio. AIDS diagnosis, the current CD4 cell count, the CD4/CD8 ratio, the plasma HIV RNA level, and cART exposure were considered as time-updated covariates.
To study the impact of cART on the risk of HZ early after treatment initiation and the possibility that HZ might be a manifestation of IRIS, we evaluated the risk of HZ during the first months of cART by using the same methodology as that used elsewhere for Hodgkin lymphoma [22] and Kaposi sarcoma [23] . For this purpose, we considered a subset of antiretroviral-naive patients who either initiated cART or remained untreated. We excluded patients who had received single or dual antiretroviral regimens prior to cART. Exposure to cART and its duration in each patient were divided into the following time-interval categories: no cART and year <1996, no cART and year ≥1996 (the reference category), and <3 months, 3-6 months, and >6 months since starting cART. The analysis used the intent-to-treat principle (ie, no changes of antiretroviral regimen were considered). Univariable and multivariable Poisson modeling was used to study the impact of the duration of cART exposure and other variables on the incidence (risk) of HZ. The first multivariable model (MV0) was adjusted for age, sex, HIV transmission group, sub-Saharan origin, and AIDS status. In 2 other multivariable models, in addition to the variables included in MV0, we added the current CD4 cell count (MV1) and the current CD4 cell count plus the current plasma HIV RNA level (MV2). To compare the risk of HZ between the HIV-infected population and the general population in France in 2005-2008, we calculated standardized incidence ratios (SIRs), which reflect the risk of HZ in HIV-infected patients relative to the general population, if the general population was demographically similar to the HIV population. SIRs were calculated by dividing the observed number of cases of incident HZ among HIV-infected patients by the expected number. Expected numbers of HZ cases were obtained by multiplying patient-years at risk in each 5-year age group of the HIV-infected population by the corresponding sex-and age-specific incidence rates in the general population.
SAS software version 9.3 (SAS Institute, Cary, North Carolina) was used for all statistical analyses.
RESULTS
Patients
Between 1992 and 2011, 91 044 HIV-infected patients from the FHDH cohort were eligible for the study and contributed 583 125 PY at risk of HZ. Incident HZ was diagnosed in 7167 patients ( Figure 1) . Characteristics of the patients with and without incident HZ are described in Table 1 .
Most patients with HZ were men (72%), and median age was 38 years. Men who have sex with men accounted for 39.6% of the HZ patients. The median CD4 count at HZ diagnosis was 304 cells/µL (nadir, 176 cells/µL). Patients with HZ were less likely than patients without HZ to have plasma HIV RNA <500 copies/mL (28.7% vs 69.3%, respectively). Figure 2 shows the incidence rate of HZ according to the calendar period, CD4 cell count, CD4/CD8 ratio, and HIV RNA level. The incidence rate declined significantly over the study period (P trend < .0001 in both men and women), from 2955 per 100 000 PY in 1992-1996 to 628 per 100 000 PY in 2009-2011, and continued to decline during the cART period (P trend < .0001). Higher incidence rates of HZ were found in men, patients with low CD4 cell counts, and low CD4/CD8 ratios, and patients with high plasma HIV RNA levels.
HZ Incidence Rate and Risk Factors
In multivariable analyses (Table 2 ), the risk of HZ was associated with age at FHDH entry, female sex, transmission group, geographic origin (lower rates in patients from sub-Saharan Africa), AIDS status, CD4 cell nadir, current and nadir CD4 cell counts, cART use, and calendar period. Compared with the period 1992-1996, a significant decline in the risk of HZ Figure 2 . Standardized incidence rates of herpes zoster among human immunodeficiency virus (HIV)-infected patients according to calendar period (A), plasma HIV RNA level (B), and CD4 cell count and CD4/CD8 ratio (C). Incidence rates are expressed as cases per 100 000 person-years (PY). Incidence rates are standardized according to the age and sex distribution of the HIV-infected patients in 1997-2011. Bars indicate 95% confidence intervals. Test of interaction between CD4 cell count and CD4/CD8 ratio, P < .0001. Table 2 , model 2) indicated that the plasma HIV RNA level and CD4/CD8 ratio were also significantly associated with the risk of HZ: HZ was more likely to occur in patients with higher plasma HIV RNA levels and in patients with CD4/CD8 ratios <0.9.
Risk of IRIS
A total of 48 616 initially ART-naive patients were included in the analysis of the early impact of cART on the HZ incidence. Among cART-naive patients, the HZ incidence was 1131/ 100 000 PY prior to 1996. After 1996, the incidence was maximal at 2275/100 000 PY during the first 3 months of cART, and declined to 742/100 000 PY after 6 months of cART. The RRs derived from Poisson regression models are given in Table 3 . Compared with untreated patients during the years 1996-2011, the crude risks of HZ were significantly elevated during the first 6 months of cART, with an RR reaching 1. Restriction to a population followed after 1997 with available plasma HIV RNA measures gave very similar estimates (not shown).
Comparison With the General Population
In the general population in [2005] [2006] [2007] [2008] , HZ occurred at a median age of 60 years and was more frequent in women than in men. The crude incidence rate was 439 per 100 000 PY in women and 351 per 100 000 PY in men. Contrary to the HIV-infected population, the incidence increased significantly with age in the general population ( Figure 3A ). After accounting for the sex and age structure of the HIV-infected population, the risk of HZ was 2.7 times higher in the HIV-infected population than in the general population (overall SIR, 2.7 [95% CI, 2.6-2.9]). In both men and women, the SIRs were highest at youngest ages ( Figure 3B ) and declined significantly across the age groups (P trend = .003). SIRs were no longer significantly different from those in the general population after 65 years of age.
DISCUSSION
This study of a large population of HIV-infected patients shows that the incidence rate of HZ in France declined significantly with the advent of cART and that it continued to decline thereafter, reaching 628/100 000 PY in 2009-2011. However, the risk of HZ in HIV-infected patients remains roughly 3 times higher than in the general population, particularly in the 15-to 44-year age group, in which the excess risk is 6-fold. The risk of HZ was associated with the degree of immunodeficiency and was greatly reduced by cART. In addition, among antiretroviral-naive patients, we found that the risk of HZ increased moderately during the first months of cART, before falling sharply thereafter.
The main strengths of our study are the very large size of the study population, the prospective follow-up in both the precART and cART eras, the lengthy follow-up in the cART era (518 764 PY), and comparison with the general population. One limitation is that, although HZ is classified as a class B clinical manifestation of HIV infection in the CDC classification, milder HZ episodes may have been underreported in the FHDH cohort, leading to an underestimation of the incidence rates. However, this underreporting is likely stable over time and would not therefore have markedly affected the observed time trends. HZ symptoms and complications such as postherpetic neuralgia are not studied in detail in the FHDH cohort, as this would require the use of a specific questionnaire. We found that the incidence of HZ in HIV-infected patients declined over time, from 2955/100 000 PY in the pre-cART period to 845/100 000 PY in 2005-2008. The incidence rate continued to decline significantly during the cART era. Most recent studies [3, 13] have shown similar trends, although some earlier reports indicated no change in the risk of HZ since the cART era [9, 24] . In our Cox multivariable model, cART was associated with a 40% decrease in the risk of HZ. Like others [7, [13] [14] [15] , we found a clear association between the CD4 cell count and the risk of HZ. The severity of immune depression, reflected by the current CD4 cell count, the CD4 cell nadir, AIDS status, and current plasma viral load, was also associated with the risk of HZ. Interestingly, we found an inverse dose-response relationship between the CD4/CD8 ratio and the risk of HZ, independent of the CD4 cell count and viral load. An association between the CD8 cell count and the risk of HZ has also been described by others [16, 17] . Overall, our results suggest that the decrease in the incidence of HZ in the cART era is due to immune restoration and viral control.
IRIS has been associated with a plethora of health disorders, including HZ. The lack of standardized IRIS definitions makes it difficult to compare the results across studies. The IRIS phenomenon is also difficult to analyze in studies that are not specifically designed to prospectively collect relevant information. A meta-analysis of the risk of IRIS in patients starting cART [25] identified only 1 study [26] that reported the risk of HZ in this context: 12.2% of patients initiating cART developed HZ. More recently, Blank et al [15] found a 4-fold higher risk of HZ during the first 3 months of cART in the United States, and a study from South Africa [27] found a 1-year incidence rate of 1810/100 000 PY after starting cART. Our data indicate that the risk of HZ is moderately elevated in the first 6 months of cART (adjusted RR, 1.5), with a peak just before the third month of treatment. After 6 months of cART, the risk fell sharply by 40% compared with untreated patients. Surprisingly, in naive patients, pre-cART RRs were lower than post-cART RRs except after 6 months of cART. Although there was no clear explanation for this, neither an indication bias with cART being given to patients more at risk of HZ, nor an undernotification of HZ in the pre-cART era when more severe diseases than HZ were competing patients' prognosis, can be excluded.
In the general population, the incidence of HZ increases with age and is higher in women [20] . By comparison with the general population, after accounting for differences in sex and age distribution, we found that the risk of HZ was 2.7 times higher in the HIV-infected population. This excess risk was higher at younger ages and maximal between ages 15 and 34 years, when it approached 6-fold, and was no longer significant in those >65 years of age. Other studies comparing the risk to that of either the general population or an HIV-uninfected population [7] also showed a higher risk in HIV-infected individuals. In other immunocompromised individuals-for example, those with cancer [28] or systemic lupus erythematosus [29] -acquired or treatment-induced immunodeficiency is also associated with an increased risk of HZ. In a study by Kaiser Permanente Northern California [28] , the risk of HZ was 4.8 times higher in patients with hematologic malignancies and 1.9 times higher in those with solid tumors than in the US general population. A US veterans' cohort [13] showed that the incidence of HZ decreased with increasing age in HIV-infected individuals, whereas it increased with age in the general veteran population [30] . Taken together, the increased risk observed here in the younger strata of HIV-infected patients suggests that the benefits and safety of VZV vaccination should be studied in HIV-infected individuals below the age recommended for vaccination in the general population.
In conclusion, the overall decrease in the incidence of HZ among HIV-infected patients in the cART era is probably related to improved immune restoration and viral control. This trend may continue in the future as cART is initiated earlier and at higher CD4 cell counts, as recommended by most recent guidelines. However, clinicians and patients should be aware that cART transiently increases the risk of HZ during the first 6 months of treatment.
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